Multicellular living organisms and unmodified parts thereof and – Method of using a transgenic nonhuman animal in an in vivo...
Reexamination Certificate
2006-09-26
2006-09-26
Qian, Celine (Department: 1636)
Multicellular living organisms and unmodified parts thereof and
Method of using a transgenic nonhuman animal in an in vivo...
C800S018000, C800S021000
Reexamination Certificate
active
07112715
ABSTRACT:
The present invention relates to a metazoan organism, with the exception of humans, and in particular a mouse, characterized in that at least one cell of this organism comprises at least one fusion protein between a recombinase Cre and a modified ligand binding domain of the nuclear estrogen receptor alpha, allowing the inactive fused recombinase to be induced by synthetic antiestrogens, but not by natural estrogens, and one or more DNA sequences of interest belonging to the genome of said organism into which one or more sites of recognition of said recombinase protein are inserted. The invention also covers the methods using said organism for the screening of medicaments, the mutagenesis and the analysis of the biological function of the DNA sequences) of interest, in particular of gene(s) of interest, such as RXRα.
REFERENCES:
patent: 6093873 (2000-07-01), Chambon et al.
patent: 0 698 392 (1996-02-01), None
patent: WO 92 06104 (1992-04-01), None
patent: WO 94 26100 (1994-11-01), None
patent: WO 95 00555 (1995-01-01), None
patent: WO 97 10819 (1997-03-01), None
patent: WO 97 31108 (1997-08-01), None
patent: WO 99 18222 (1999-04-01), None
patent: WO 99 25851 (1999-05-01), None
patent: WO 00 49147 (2000-08-01), None
Campbell and Wilmut. Totipotency or Multipotentiality of Cultured Cells: Applications and Progress. Theriogenology. Jan. 1, 1997. Vol. 47, No. 1, pp. 63-70.
Jacks et al. Effects of an Rb mutation in the mouse. Sep. 24, 1992. Nature. vol. 359, pp. 295-300.
Bradley et al. Modifying the Mouse: Design Desire. May 1992. Biotechnology. vol. 10, pp. 534-539.
Mullins and Mullins. Perspective Series: Molecular Medicine in Genetically Engineered Animals. Apr. 1, 1996. Clinical Investigation. vol. 97, No. 7, pp. 1557-1560.I
Sigmund. Viewpoint: Are Studies in Genetically Altered mice Out of Control? Jun. 2000. Arterioscler Thromb. Vasc. Biol. vol. 20. pp. 1425-1429.
Wall. Transgenic Livestock: Progress and Prospects for the Future. 1996. Theriogenology. vol. 45, pp. 57-68.
Indra et al. Nucleic Acid Research, 1999. vol. 27, p. 4324-4327.
Feil et al. PNAS, 1996, vol. 93, pp. 10887-10890.
Schwenk et al. Nucleic Acid Research, 1998. vol. 26, p. 1427-1432.
Ross et al. PNAS, 1990. vol. 87, p. 9590-9594.
Tontonoz et al. PNAS, 1997, vol. 94, pp. 237-241.
Indra A. et al., Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases, Nucleic Acids Research, Nov. 15, 1999, pp. 4324-4327, vol. 27, No. 22, Oxford University Press, Surrey, GB.
Vasioukhin V. et al., The magical touch: Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin, Proceedings of the National Academy of Sciences of USA, Jul. 20, 1999, pp. 8551-8556, vol. 96, No. 15.
Raghavan S. et al., Conditional ablation of betal integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination, The Journal of Cell Biology, Sep. 4, 2000, pp. 1149-1160, vol. 150, No. 5.
Feng X. et al., Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids, Genes & Development, 1997, pp. 59-71, vol. 11, No. 1.
Saltou M. et al., Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor, Nature, Mar. 9, 1995, pp. 159-162, vol. 374, MacMillan Journals Ltd., London, GB.
Li M. et al., Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis, Nature, Oct. 5, 2000, pp. 633-636, vol. 407, No. 6804.
Kastner P. et al., Vitamin A deficiency and mutations of RXRalpha, RXRbeta and RARalpha lead to early differentiation of embryonic ventricular cardiomyocytes, Development, Dec. 1997, pp. 4749-4758, vol. 124, No. 23.
Sumi-Ichinose C. et al., SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells, Mol. Cell Biol., Oct. 1997, pp. 5976-5986, vol. 17, No. 10.
Feil R. et al., Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochemical and Biophysical Research Communications, Aug. 28, 1997, pp. 752-757, vol. 237, No. 3.
Metzger D. et al., Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase, Proceedings of the National Academy of Sciences of USA, Jul. 18, 1995, pp. 6991-6995, vol. 92, No. 15, National Academy of Science, Washington, USA.
Metzger D. et al., Engineering the mouse genome by site-specific recombination, Current Opinion in Biotechnology, Oct. 1999, pp. 470-476, vol. 10, No. 5, London, GB.
Barlow C. et al., Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments, Nucleic Acids Research, 1997, pp. 2543-2545, vol. 25, No. 12.
Imai T. et al., Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes, Proceedings of the National Academy of Sciences of USA, Jan. 2, 2001, pp. 224-228, vol. 98, No. 1, USA.
Imai T. et al., Inducible site-specific somatic mutagenesis in mouse hepatocytes, Genesis, Feb. 2000, pp. 147-148, No. 2, Wiley-Liss, New York, NY, US.
Wan Y. et al., Hepatocyte-specific mutation established retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver, Mol. Cell Biol., Jun. 2000, pp. 4436-4444, vol. 20, No. 12.
Mahfoudi A. et al., Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists, Proceedings of the National Academy of Sciences of the United States, 1995, pp. 4206-4210, vol. 92, No. 10.
Chambon Pierre
Metzger Daniel
Foley & Lardner LLP
Gie-Cerbm, Centre Europeen de Recherche en Biologie et en Medeci
Qian Celine
LandOfFree
Transgenic mouse for targeted recombination mediated by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mouse for targeted recombination mediated by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse for targeted recombination mediated by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528230